Roger F. Butterworth; Gilles Pomier Layrargues Hepatic Encephalopathy 9781461288510

Варианты приобретения

Цена: 21661.00р.
Кол-во:
Наличие: Поставка под заказ. Есть в наличии на складе поставщика.
Склад Америка: Есть
При оформлении заказа до: 2025-07-28
Ориентировочная дата поставки: Август-начало Сентября
При условии наличия книги у поставщика.

Добавить в корзину

в Мои желания

Автор: Roger F. Butterworth; Gilles Pomier Layrargues
Название: Hepatic Encephalopathy
ISBN: 9781461288510
Издательство: Springer
Классификация:

Науки о жизни (медико-биологические): общие вопросы

Нейронауки

ISBN-10: 1461288517
Обложка/Формат: Paperback
Страницы: 622
Вес: 0.89 кг.
Дата издания: 17.09.2011
Серия: Experimental Biology and Medicine
Язык: English
Размер: 234 x 156 x 33
Основная тема: Biomedicine
Подзаголовок: Pathophysiology and Treatment
Ссылка на Издательство: Link
Рейтинг:
Поставляется из: Германии
Описание: Hepatic Encephalopathy (HE) is a neuropsychiatric disorder resul t- ing from liver failure. HE may be associated with fulminant (acute) hepatic failure or chronic liver disease with portal-systemic shunting. The latter condition is characterized neuropathologically by astro- cytic rather than neuronal changes (Alzheimer Type II astrocytosis). The former is frequently accompanied by cerebral edema. Several hypotheses have been proposed to explain the pathogene- sis of HE. These include: 1. A toxic action of a substance (or substances) such as ammonia on brain function 2. A deficit of cerebral energy metabolism 3. Neurotransmitter changes, and, more recently 4. The role of endogenous benzodiazepines. This volume summarizes the results of a symposium held in Val David, Quebec from October 3D-November I, 1988, that was devoted to an evaluation of the evidence for and against the various hypothe- ses of HE. Data from studies in patients, in experimental (animal) models of HE, and in cultured cell preparations were discussed. In addition, a review of available approaches to the treatment and man- agement of HE was included. The therapeutic use of lactulose, anti- biotics, dietary treatment, and branched-chain amino acid treatments were included, as well as the results of preliminary studies of the therapeutic use of the benzodiazepine antagonist, flumazenil. Roger F. Butterworth, PhD Gilles Pomier Layrargues, MD v Acknowledgments The symposium was made possible by the generous financial assistance of: Hoffman-La Roche Ltd.

Hepatic Encephalopathy, Roger F. Butterworth; Gilles Pomier Layrargues